Is SMMT a Buy? What to Consider in 2026
Short answer
The bull case for Summit Therapeutics (SMMT) rests on Ivonescimab FDA review and first approval: The FDA has accepted Summit's BLA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC patients who progressed after TKI therapy, with a target decision date of November 14, 2026. Product revenue (TTM) is ~$0 (pre-commercial). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab; a failed trial, a negative or delayed FDA decision, or unexpected safety findings could sharply reduce the company's value. Whether SMMT is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Summit Therapeutics is a clinical-stage biopharmaceutical company focused almost entirely on ivonescimab, a first-in-class tetravalent bispecific antibody that targets both PD-1 and VEGF simultaneously. Summit in-licensed ivonescimab from China's Akeso in January 2023 and holds rights to develop and commercialize it across North America, South America, Europe, the Middle East, Africa, and Japan, while Akeso keeps China and certain other regions. The lead opportunity is non-small cell lung cancer (NSCLC), where Phase III data have shown ivonescimab extending progression-free survival versus Merck's Keytruda (pembrolizumab), plus additional programs in colorectal and other cancers. The company generates no meaningful product revenue yet and funds operations from its cash balance while running large global trials. The investment picture is that of a high-risk, high-reward binary biotech. Summit's roughly $12 billion market value (July 2026) rests on expectations for ivonescimab rather than on sales or profits, so the stock is driven by catalysts: the FDA has accepted a Biologics License Application with a target decision (PDUFA) date of November 14, 2026, and multiple Phase III readouts (HARMONi-3, HARMONi-7) are due in 2027. Positive data or approval could unlock a large commercial market against a Keytruda franchise worth tens of billions, but a single trial miss, a regulatory setback, or the need to raise more cash could sharply cut the value. This is a speculative, event-driven holding, not an income or earnings stock.
What's the case for buying SMMT?
1. Ivonescimab FDA review and first approval.
The FDA has accepted Summit's BLA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC patients who progressed after TKI therapy, with a target decision date of November 14, 2026. This would be the drug's first US approval and the company's first potential commercial product. The decision is a major binary catalyst that could reprice the stock in either direction.
2. Head-to-head data versus Keytruda.
Phase III studies have shown ivonescimab roughly doubling progression-free survival versus Keytruda (pembrolizumab) monotherapy in PD-L1-positive NSCLC in China, and the HARMONi-6 study reported a statistically significant overall survival benefit in squamous NSCLC. If global confirmatory trials such as HARMONi-3 (versus pembrolizumab plus chemotherapy, results expected 2027) and HARMONi-7 replicate that advantage, ivonescimab could challenge the largest oncology franchise in the world. These readouts are the central swing factors for the stock.
3. Pipeline breadth and partnerships.
Summit is expanding ivonescimab beyond first-line NSCLC into colorectal cancer (the AK112-206 Phase II with data at ASCO 2026) and other tumor types, and announced a clinical collaboration with GSK to combine ivonescimab with GSK's B7-H3 antibody drug conjugate. Over 4,000 patients have been treated with ivonescimab in trials globally, plus over 70,000 in the commercial setting in China through Akeso. Broader indications and combinations could widen the eventual market opportunity.
4. Cash runway to fund late-stage trials.
Summit ended the first quarter of 2026 with about $598.7 million in cash, equivalents, and short-term investments, down from roughly $713.4 million at the end of 2025, with net cash used in operations of about $122.3 million in the quarter. That balance funds the large ongoing Phase III program and pre-launch preparation. Because the company is pre-revenue, sustained burn means additional capital raises are possible, which could dilute existing shareholders.
What are the risks to SMMT?
Summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab; a failed trial, a negative or delayed FDA decision, or unexpected safety findings could sharply reduce the company's value. The competitive field is intensifying, with Pfizer/3SBio and Bristol Myers Squibb/BioNTech (pumitamig) also developing PD-1/PD-L1 by VEGF bispecifics, and Merck's Keytruda is the entrenched standard of care. The company depends on its license from Akeso and on manufacturing and clinical execution across many regions. With ongoing cash burn and no product sales, Summit may need to raise capital, diluting shareholders, and its stock is highly volatile and prone to large single-day moves around catalysts.
How is SMMT valued? (as of JULY 2026)
Snapshot for SMMT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Product revenue (TTM): ~$0 (pre-commercial)
- Cash & short-term investments (Q1 2026): ~$598.7 million
- Quarterly operating cash burn (Q1 2026): ~$122.3 million
- Market cap: ~$12 billion
- Share price: ~$15
- Shares outstanding: ~776 million
- Lead-drug FDA decision (PDUFA): ~November 14, 2026
As a clinical-stage biotech with no meaningful product sales, Summit cannot be valued on earnings or a P/E ratio; its roughly $12 billion market value (July 2026) reflects expectations for ivonescimab rather than current financials. Standard metrics like revenue and profit are near zero, so investors weigh trial data, the market size of NSCLC, and cash runway instead. Valuation is therefore speculative and can move dramatically on a single readout or regulatory event.
How do you decide if SMMT is a buy?
Rather than asking whether SMMT is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold SMMT indirectly through an index or sector ETF before adding more.
For the full picture, see the SMMT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about SMMT against your real portfolio and see your actual exposure before deciding.
The bottom line on SMMT
The bottom line: Summit Therapeutics's story right now is Ivonescimab FDA review and first approval, with product revenue (ttm) at ~$0 (pre-commercial). If you believe that narrative continues, the call is about sizing SMMT sensibly and checking overlap with what you own; if you doubt it (the risk: summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab; a failed trial, a negative or delayed FDA decision, or unexpected safety findings could sharply reduce the company's value.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around SMMT with Walnut
Use Summit Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is SMMT a good stock to buy right now?
+
The case for Summit Therapeutics right now is Ivonescimab FDA review and first approval, with product revenue (ttm) at ~$0 (pre-commercial). If you believe that thesis holds, SMMT is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab; a failed trial, a negative or delayed FDA decision, or unexpected safety findings could sharply reduce the company's value. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Summit Therapeutics do?
+
Summit Therapeutics is a clinical-stage biopharmaceutical company focused almost entirely on ivonescimab, a first-in-class tetravalent bispecific antibody that targets both PD-1 an
What are the main risks of SMMT?
+
Summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab; a failed trial, a negative or delayed FDA decision, or unexpected safety findings could sharply reduce the company's value. The competitive field is intensifying, with Pfizer/3SBio and Bristol Myers Squibb/BioNTech (pumitamig) also developing PD-1/PD-L1 by VEGF bispecifics, and Merck's Keytruda is the entrenched standard of care. The company depends on its license from Akeso and on manufacturing and clinical execution across many regions. With ongoing cash burn and no product sales, Summit may need to raise capital, diluting shareholders, and its stock is highly volatile and prone to large single-day moves around catalysts.
What does Summit Therapeutics do?
+
Summit Therapeutics is a clinical-stage biopharmaceutical company developing ivonescimab, a bispecific antibody that blocks both PD-1 and VEGF. Its main focus is treating non-small cell lung cancer, with additional programs in colorectal and other cancers. It does not yet sell an approved product.
What is ivonescimab?
+
Ivonescimab is a first-in-class tetravalent bispecific antibody that targets PD-1 and VEGF at the same time. Summit licensed it from China-based Akeso in 2023 and is developing it for lung and other cancers. In trials it has extended progression-free survival versus Merck's Keytruda in some NSCLC settings.
Is Summit Therapeutics profitable?
+
No. Summit is a pre-revenue clinical-stage biotech with no meaningful product sales, so it runs net losses and burns cash funding its trials. It reported about $122.3 million of operating cash use in the first quarter of 2026. Profitability would depend on approving and commercializing ivonescimab.
When is the FDA decision on ivonescimab?
+
The FDA accepted Summit's Biologics License Application for ivonescimab plus chemotherapy in EGFR-mutated NSCLC patients who progressed after TKI therapy, with a target decision (PDUFA) date of November 14, 2026. That decision is a major catalyst for the stock and could move it sharply either way.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell SMMT; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.